Developing a Minimally Structured Mathematical Model of Cancer Treatment with Oncolytic Viruses and Dendritic Cell Injections
暂无分享,去创建一个
[1] Hoguen Kim,et al. Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[2] F. Emmert-Streib. Personalized medicine: Has it started yet? A reconstruction of the early history , 2013, Front. Genet..
[3] Eduardo D Sontag,et al. Evaluating optimal therapy robustness by virtual expansion of a sample population, with a case study in cancer immunotherapy , 2017, Proceedings of the National Academy of Sciences.
[4] Manuel Arruebo,et al. Assessment of the Evolution of Cancer Treatment Therapies , 2011, Cancers.
[5] I. Sobola,et al. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo estimates , 2001 .
[6] J. Blay,et al. Personalized medicine in oncology: where have we come from and where are we going? , 2013, Pharmacogenomics.
[7] M. Verma. Personalized Medicine and Cancer , 2012, Journal of personalized medicine.
[8] Nicholas R. Lemoine,et al. Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles , 2010, Viruses.
[9] J. Gunawardena. Models in Systems Biology: The Parameter Problem and the Meanings of Robustness , 2010 .
[10] R. Coffey,et al. Volume of Preclinical Xenograft Tumors Is More Accurately Assessed by Ultrasound Imaging Than Manual Caliper Measurements , 2010, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[11] Joanna R. Wares,et al. Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. , 2015, Mathematical biosciences and engineering : MBE.
[12] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .
[13] G. Schwarz. Estimating the Dimension of a Model , 1978 .
[14] Adelle C F Coster,et al. Mathematical Modelling of the Interaction Between Cancer Cells and an Oncolytic Virus: Insights into the Effects of Treatment Protocols , 2018, Bulletin of mathematical biology.
[15] Raluca Eftimie,et al. Tumour-associated macrophages and oncolytic virotherapies: a mathematical investigation into a complex dynamics , 2018 .
[16] Yuri Kogan,et al. Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models , 2010, PloS one.
[17] P. Fisher,et al. Gene Therapies for Cancer: Strategies, Challenges and Successes , 2015, Journal of cellular physiology.
[18] Hulin Wu,et al. Differential Equation Modeling of HIV Viral Fitness Experiments: Model Identification, Model Selection, and Multimodel Inference , 2009, Biometrics.
[19] Mads Kærn,et al. Model-based rational design of an oncolytic virus with improved therapeutic potential , 2013, Nature Communications.
[20] M. Goulian,et al. Robustness and the cycle of phosphorylation and dephosphorylation in a two-component regulatory system , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[21] S. Leibler,et al. Robustness in simple biochemical networks , 1997, Nature.
[22] Hoguen Kim,et al. Therapeutic and Tumor-specific Immunity Induced by Combination of Dendritic Cells and Oncolytic Adenovirus Expressing IL-12 and 4-1BBL. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] L. G. Pillis,et al. A Comparison and Catalog of Intrinsic Tumor Growth Models , 2013, Bulletin of mathematical biology.
[24] Dominik Wodarz,et al. Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.
[25] K. S. Brown,et al. Statistical mechanical approaches to models with many poorly known parameters. , 2003, Physical review. E, Statistical, nonlinear, and soft matter physics.
[26] H. Enderling,et al. Fighting Cancer with Mathematics and Viruses , 2017, Viruses.
[27] C. Figdor,et al. Dendritic Cell–Based Immunotherapy: State of the Art and Beyond , 2016, Clinical Cancer Research.
[28] David Hinkley,et al. Bootstrap Methods: Another Look at the Jackknife , 2008 .
[29] Jeremy Gunawardena,et al. Programming with models: modularity and abstraction provide powerful capabilities for systems biology , 2009, Journal of The Royal Society Interface.
[30] Christopher R. Myers,et al. Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..
[31] Dominik Wodarz,et al. ODE models for oncolytic virus dynamics. , 2010, Journal of theoretical biology.
[32] Joanna R. Wares,et al. Quantitative impact of immunomodulation versus oncolysis with cytokine-expressing virus therapeutics. , 2015, Mathematical biosciences and engineering : MBE.
[33] G. Trinchieri,et al. Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.
[34] Charles Swanton,et al. Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.
[35] Clifford M. Hurvich,et al. Regression and time series model selection in small samples , 1989 .
[36] J. Feldman. A MATHEMATICAL MODEL FOR TUMOR VOLUME EVALUATION USING TWO-DIMENSIONS , 2010 .
[37] T. Watts,et al. 4-1BB Ligand-Mediated Costimulation of Human T Cells Induces CD4 and CD8 T Cell Expansion, Cytokine Production, and the Development of Cytolytic Effector Function1 , 2002, The Journal of Immunology.
[38] Flavio Cannavó,et al. Sensitivity analysis for volcanic source modeling quality assessment and model selection , 2012, Comput. Geosci..
[39] K. J. Mahasa,et al. Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach , 2017, PloS one.
[40] B. Efron. Bootstrap Methods: Another Look at the Jackknife , 1979 .
[41] T. Bekaii-Saab,et al. The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies , 2017, Biomedicines.
[42] Seth Sullivant,et al. Identifiability Results for Several Classes of Linear Compartment Models , 2014, Bulletin of Mathematical Biology.
[43] L. Aurelian. Oncolytic viruses as immunotherapy: progress and remaining challenges , 2016, OncoTargets and therapy.